Assessing Compliance with Reporting Requirements in European Phase II to IV Clinical Trials: A Cross-Sectional Observational Study

This cross-sectional study of 7,547 European Phase II–IV clinical trials reveals that while registration data quality on the new CTIS platform is high, sponsor compliance with legal results reporting requirements remains weak, with fewer than half of the trials legally obligated to report doing so within the required timeframe.

The Gist

Imagine the world of medical research as a massive, global library. For years, this library had a major problem: while people were writing thousands of new books (clinical trials) about how to treat diseases, many of those books were never put on the shelves. Some were hidden in the back room, some were left unfinished, and some were just blank pages. This meant doctors and patients were often making decisions based on incomplete information, like trying to solve a puzzle with half the pieces missing.

To fix this, Europe built a brand-new, state-of-the-art digital library called CTIS (Clinical Trial Information System). The rules were strict and clear: If you write a book (run a drug trial), you must register it before you start, and you must put the final story (the results) on the shelf within a specific time—12 months for adults, 6 months for children. The promise was that this new system would bring "transparency never seen before."

This study is like a library inspector who walked through the new building to see if the rules were actually being followed. Here is what they found, broken down simply:

1. The Sign-In Sheet was Perfect

First, the inspectors checked the "sign-in sheets" (the registration data). They wanted to see if every book had a proper title, author, and description when it was first registered.

• The Verdict: The sign-in sheets were almost flawless. Over 99% of the information was there. The new system works great for starting a trial.

2. The "Story" Was Missing for Half the Books

Next, the inspectors looked at the books that were supposed to be finished and put on the shelves. They looked at 234 trials that had legally finished and were due for reporting.

• The Verdict: Only about half (49.6%) of the sponsors actually put their finished stories on the shelves on time.
  • The Good News: 20% of the latecomers eventually showed up, just a bit late.
  • The Bad News: About 42% of the sponsors simply didn't show up at all. They didn't upload the results.

3. The "Fake" or "Blank" Pages

Even among the people who did upload a document, the quality was often poor. The inspectors found 47 trials where the sponsor uploaded a file, but it wasn't a real "story."

• The "We Haven't Read It Yet" excuse: Some documents said, "We are still analyzing the data," even though the trial ended years ago.
• The "It Was a Strategic Decision" excuse: Some said, "We stopped the study for business reasons," but didn't explain what happened to the patients who were already in it.
• The "Redacted" mystery: Some documents had huge blacked-out sections (redactions) where the important numbers should have been, making the story impossible to read.
• The "Vague" summary: Some just wrote, "Most people felt okay," without giving the actual numbers.

4. The Librarians (Regulators) Are Sleeping at the Wheel

The most surprising part of the story is why this is happening. The European regulators (the librarians in charge of the CTIS system) have the power to punish sponsors who break the rules. However, the study found that no one has been punished yet.

• It's like a school where students are told, "If you don't turn in your homework, you get detention," but the teacher never actually gives out detentions. Because there are no consequences, many sponsors just ignore the rules.

The Big Picture

The study concludes that while the new library building (CTIS) is beautiful and the sign-in process is perfect, the rules for finishing the books are being ignored.

• Why does this matter? If we don't know the results of these trials, we might keep using drugs that don't work, or stop using drugs that do work. It wastes money and, more importantly, puts patient safety at risk.
• What needs to happen? The study suggests that the "librarians" need to wake up. They need to start checking the books more carefully, flagging the missing ones, and actually punishing the sponsors who refuse to share their results.

In short: Europe built a great new system to share medical knowledge, but half the people who promised to share their findings are still hiding in the shadows, and the people in charge haven't done enough to bring them into the light.

Technical Summary

1. Problem Statement

Despite global efforts to enhance clinical trial transparency, significant gaps remain in the availability of registration data and results. Previous European registries (EudraCT) suffered from missing data and low compliance, with sponsors failing to report results for 20–47% of trials. In January 2022, the European Union implemented the Clinical Trial Information System (CTIS) under the new Clinical Trials Regulation. This regulation legally mandates sponsors to prospectively register all Phase II–IV drug trials and publish summary results (both scientific and layperson versions) within 12 months for adult trials and 6 months for pediatric trials.

However, it was unclear whether this new regulatory framework and the CTIS platform had successfully achieved the promised "high levels of transparency." There was a lack of empirical data regarding:

• The data quality of the new CTIS registry.
• The actual compliance rate of sponsors with legal reporting deadlines.
• The quality of the uploaded results documents (i.e., whether they contained complete outcome data).

2. Methodology

This was a cross-sectional observational study conducted as of November 10, 2025.

• Data Source: The study analyzed the entire cohort of 7,547 Phase II–IV clinical trials registered on CTIS.
• Study Population: From the total cohort, researchers identified 277 trials that were legally required to report results (trials that had ended).
  • Categorization: Trials were classified as "paediatric" (enrolling minors or part of a Paediatric Investigation Plan) or "adult."
  • Exclusions: Trials were excluded if they were granted a legal extension for reporting or if documents indicated they were "cancelled" (closed without enrolling participants). This left a final analytical cohort of 234 trials.
• Data Extraction & Validation:
  • Registration Quality: Researchers manually reviewed 17 data columns across the 7,547 trials to quantify missing data points and check for data normalization.
  • Results Compliance: For the 234 due trials, researchers manually downloaded and reviewed the uploaded scientific summary results (PDFs).
  • Compliance Criteria: A trial was deemed "fully reported" only if the document contained:
    1. The number of participants enrolled.
    2. Outcomes for all primary outcome measures.
    3. A corresponding layperson summary document.
  • Tools: Analyses were performed using R (version 4.4.2). The study protocol was prospectively registered on OSF.

3. Key Contributions

• First Assessment of CTIS: This is the inaugural study evaluating data quality and legal compliance specifically on the new European CTIS platform.
• Granular Compliance Analysis: Unlike previous studies that often relied on binary "reported/not reported" metrics, this study distinguished between:
  • Timely compliance.
  • Late reporting.
  • Non-compliance due to missing data (e.g., results never analyzed, vague narratives, or redacted data).
• Global Implications: The study provides a critical case study for the World Health Organization (WHO) and other global registries currently implementing similar direct-result-upload functions, highlighting the necessity of quality assurance mechanisms.

4. Key Results

A. Registration Data Quality

• Data quality on CTIS is high. Only 0.2% (319/128,299) of expected data points were missing across the 7,547 trials.
• Data normalization was 100% for applicable columns, though minor inconsistencies in sponsor naming conventions were noted.

B. Reporting Compliance

• Overall Compliance: Of the 234 trials legally required to report, only 49.6% (116 trials) were fully compliant with legal requirements (on-time, complete scientific and layperson results).
• Breakdown of Non-Compliance:
  • Late Reporting: 8.5% (20 trials) reported results but missed the deadline.
  • Non-Reporting/Incomplete: 41.9% (98 trials) failed to fully report.
    • 47 trials had no scientific results document uploaded.
    • 47 trials uploaded documents that were inadequate (e.g., stated "results never analyzed," "analyses ongoing," vague narratives, or contained redacted data).
• Timeliness: Among the 136 trials that eventually reported results, the mean reporting time was 278 days (327 days for adults, 192 days for pediatrics).
• Demographic Differences: Compliance rates were statistically similar between adult trials (50.0%) and pediatric trials (48.7%).

C. Document Quality Issues

• Many "results" documents failed to meet legal standards. Common issues included:
  • Claims that results were never analyzed due to strategic decisions.
  • Vague narrative descriptions lacking numerical data.
  • Redaction of key study arms or outcomes.
  • Lack of English language versions (documents were found in Danish, French, Italian, and Spanish).

5. Significance and Conclusions

Regulatory Failure: The study concludes that sponsor compliance with EU legal reporting requirements is weak. Despite the new regulation, regulators (EMA and national agencies) have not effectively enforced the law or performed sufficient quality assurance on uploaded documents. Less than half of the applicable trials are currently compliant.

Systemic Implications:

• Quality Assurance Gap: The study highlights that simply allowing sponsors to upload unstructured PDFs is insufficient. Without rigorous quality assurance (similar to the structured, expert-reviewed model used by ClinicalTrials.gov), registries will continue to host "results" that do not contribute to the medical evidence base.
• Global Warning: As global registries adopt similar direct-upload functions based on 2025 WHO guidelines, they face the same risk of poor data quality unless they secure funding for manual review and enforcement mechanisms.
• Policy Recommendations: The authors suggest that regulators must move beyond passive monitoring. Proposed solutions include:
  • Publicly flagging unreported trials on CTIS.
  • Integrating compliance dashboards.
  • Using AI or manual review to audit uploaded documents.
  • Enforcing existing legal sanctions against non-compliant sponsors.

Conclusion: While the CTIS platform has successfully improved the registration data quality, it has failed to ensure results transparency. The current enforcement mechanisms are insufficient to meet the legal mandates of the European Clinical Trials Regulation.